Cargando…
Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis
BACKGROUND: An effective vaccine response is currently a critical issue in the control of COVID-19. Little is known about humoral and cellular immunity comparing protein-based vaccine with other types of vaccines. The relevance of basal immunity to antibody production is also unknown. METHODS: Seven...
Autores principales: | Song, Ying-Chyi, Liu, Shih-Jen, Lee, Hui-Ju, Liao, Hung-Chun, Liu, Chuan-Teng, Wu, Mei-Yao, Yen, Hung-Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065040/ https://www.ncbi.nlm.nih.gov/pubmed/37055256 http://dx.doi.org/10.1016/j.jmii.2023.03.008 |
Ejemplares similares
-
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities
por: Chiu, Chun-Hsiang, et al.
Publicado: (2022) -
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
por: Cheng, Wen-Chien, et al.
Publicado: (2023) -
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023) -
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023) -
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
por: Chen, Chieh-Lung, et al.
Publicado: (2022)